INGELHEIM AM RHEIN, Germany – Boehringer Ingelheim today announced new data from the global Phase III FIBRONEER™ program on nerandomilast, an investigational oral preferential PDE4B inhibitor, which is currently not approved for use. The new pooled analyses, the first to demonstrate a nominally significant reduction in risk of death across...
treatment News
Posaconazole was non-inferior to voriconazole for the primary treatment of invasive aspergillosis, according to an international, randomized, double-blind, double-dummy, controlled non-inferiority trial published in the Lancet. Between October 25, 2013, and September 10, 2019, investigators randomly assigned 585 participants to receive either posaconazole or voriconazole. In the posaconazole group, 288 participants...
SAN DIEGO, CA — Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlighted recent progress across the company’s cell and gene therapy portfolio and provided updates on anticipated upcoming milestones. “In 2023, we made...
SAN DIEGO, Calif. — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1. Results...
MELBOURNE, Australia – Neuren Pharmaceuticals Limited (ASX: NEU) has received clear and constructive guidance from the FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes. All three syndromes are serious neurological disorders that emerge in early childhood and have no...
New York, NY – OS Therapies Inc. (NYSE American: OSTX)(“OS Therapies” or “the Company”), the world leader in listeria-based cancer immunotherapies, today announced that it held a successful Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Phase 2b human clinical trial of OST-HER2 in the...
Basel, Switzerland – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction,...
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved...
Announcing the results of the TALENTACE study for unresectable hepatocellular carcinoma eligible for transarterial chemoembolization (TACE) without prior systemic treatment The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of TACE-progression-free survival (TACE PFS), and overall survival (OS) is immature at the prespecified first interim...
STOCKHOLM – Swedish Orphan Biovitrum AB (publ) (Sobi™) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (GLOBE NEWSWIRE) today reported positive top-line results from the phase 3 PRINCE study evaluating the efficacy and safety of pegcetacoplan in adults with paroxysmal nocturnal haemoglobinuria (PNH) who are treatment naïve, meaning they had not received a...